Cornerstone Capital Management Holdings LLC. acquired a new stake in AveXis Inc (NASDAQ:AVXS) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 10,700 shares of the company’s stock, valued at approximately $1,034,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Nicholas Investment Partners LP bought a new stake in shares of AveXis in the 3rd quarter valued at $3,609,000. Westfield Capital Management Co. LP bought a new position in AveXis during the 3rd quarter worth about $39,563,000. Schwab Charles Investment Management Inc. increased its holdings in AveXis by 25.4% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 108,513 shares of the company’s stock worth $10,497,000 after purchasing an additional 21,993 shares in the last quarter. Wells Fargo & Company MN increased its holdings in AveXis by 59.6% during the 3rd quarter. Wells Fargo & Company MN now owns 26,170 shares of the company’s stock worth $2,531,000 after purchasing an additional 9,769 shares in the last quarter. Finally, Amalgamated Bank increased its holdings in AveXis by 19.6% during the 3rd quarter. Amalgamated Bank now owns 3,187 shares of the company’s stock worth $308,000 after purchasing an additional 523 shares in the last quarter. Institutional investors and hedge funds own 92.88% of the company’s stock.

In related news, insider Brian K. Kaspar sold 15,000 shares of the firm’s stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $101.46, for a total value of $1,521,900.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Sukumar Nagendran sold 1,780 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $101.26, for a total transaction of $180,242.80. Following the completion of the sale, the vice president now owns 1,780 shares of the company’s stock, valued at $180,242.80. The disclosure for this sale can be found here. Insiders sold a total of 52,340 shares of company stock valued at $5,172,298 in the last 90 days. 18.60% of the stock is owned by corporate insiders.

AVXS has been the subject of a number of research reports. Barclays initiated coverage on AveXis in a report on Wednesday, September 6th. They set an “overweight” rating and a $124.00 target price for the company. Nomura initiated coverage on AveXis in a report on Monday, August 28th. They set a “reduce” rating and a $52.00 target price for the company. Zacks Investment Research upgraded AveXis from a “hold” rating to a “buy” rating and set a $112.00 target price for the company in a report on Tuesday, October 24th. Instinet initiated coverage on AveXis in a report on Tuesday, August 29th. They set a “reduce” rating and a $52.00 target price for the company. Finally, Bank of America lowered their target price on AveXis from $115.00 to $112.00 and set a “buy” rating for the company in a report on Friday, November 10th. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and thirteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $110.67.

AveXis Inc (NASDAQ:AVXS) opened at $109.15 on Friday. The firm has a market capitalization of $3,570.00 and a PE ratio of -19.56. AveXis Inc has a 1-year low of $46.41 and a 1-year high of $109.60.

AveXis (NASDAQ:AVXS) last announced its quarterly earnings data on Thursday, November 9th. The company reported ($1.52) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.48) by ($0.04). During the same quarter in the prior year, the company posted ($0.87) earnings per share. equities analysts forecast that AveXis Inc will post -6.19 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://theolympiareport.com/2017/12/24/cornerstone-capital-management-holdings-llc-takes-position-in-avexis-inc-avxs.html.

AveXis Company Profile

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Want to see what other hedge funds are holding AVXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AveXis Inc (NASDAQ:AVXS).

Institutional Ownership by Quarter for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with Analyst Ratings Network's FREE daily email newsletter.